What do serum insulin, C‑peptide, and proinsulin measurements indicate in a hypoglycemic patient?

What Insulin, C-Peptide, and Proinsulin Measurements Indicate in Hypoglycemia

These three measurements distinguish whether hypoglycemia is caused by endogenous insulin overproduction (insulinoma, nesidioblastosis) versus exogenous insulin administration versus non-insulin-mediated mechanisms. 1

Normal Physiological Response to Hypoglycemia

During true hypoglycemia (plasma glucose ≤55 mg/dL or 3.0 mmol/L), the body's normal response is to completely suppress insulin secretion, resulting in: 1

• Insulin <3 µU/mL (18 pmol/L)
• C-peptide <0.6 ng/mL (0.2 nmol/L)
• Proinsulin <5.0 pmol/L

Any elevation above these thresholds during documented hypoglycemia indicates inappropriate insulin secretion and requires further investigation. 1

Diagnostic Patterns During Hypoglycemia

Pattern 1: Endogenous Hyperinsulinism (Insulinoma/Nesidioblastosis)

Both insulin AND C-peptide are elevated together: 1, 2

• Insulin ≥3 µU/mL (≥18 pmol/L)
• C-peptide ≥0.6 ng/mL (≥0.2 nmol/L)
• Proinsulin ≥5.0 pmol/L

This pattern has ~100% sensitivity and specificity for endogenous hyperinsulinism when glucose is ≤45 mg/dL (2.5 mmol/L). 2 More recent data suggests even better performance with C-peptide ≥0.30 nmol/L at glucose <2.3 mmol/L (sensitivity 96%, specificity 100%). 3

Proinsulin >5 pmol/L provides 100% diagnostic specificity and sensitivity for endogenous hyperinsulinism when glucose is below 2.5 mmol/L. 4

Pattern 2: Exogenous Insulin (Factitious Hypoglycemia)

High insulin with LOW C-peptide: 2

• Insulin markedly elevated (often >3 µU/mL)
• C-peptide <0.6 ng/mL (suppressed)
• Proinsulin low

This pattern is diagnostic for surreptitious insulin injection because exogenous insulin does not contain C-peptide and suppresses endogenous insulin production. 2

Critical pitfall: Some rapid-acting or long-acting insulin analogs (lispro, aspart, glargine) may not be detected by certain insulin assays, potentially showing falsely low insulin levels despite exogenous administration. 2 Therefore, C-peptide measurement is mandatory to avoid missing factitious hypoglycemia. 5

Pattern 3: Sulfonylurea/Meglitinide Ingestion

Both insulin and C-peptide elevated (mimics insulinoma), but: 1, 2

• Oral hypoglycemic agent screen is positive
• Pattern identical to endogenous hyperinsulinism biochemically

Always screen for sulfonylureas and meglitinides when evaluating unexplained hyperinsulinemic hypoglycemia. 1, 6

Pattern 4: Insulin Autoimmune Syndrome (Hirata Disease)

Both insulin and C-peptide appear elevated, but: 2, 7

• Insulin antibodies are present (positive test)
• Antibodies bind insulin and proinsulin, prolonging their half-life
• C-peptide immunoreactivity may be artifactually elevated due to proinsulin cross-reactivity in some assays

Routine measurement of insulin antibodies is recommended in all hypoglycemia workups to identify this rare cause. 1, 2

Why Each Marker Matters

C-Peptide: The Most Reliable Marker

C-peptide is superior to insulin for diagnosing endogenous hyperinsulinism because: 2, 8

• Released in equimolar amounts with endogenous insulin during proinsulin processing
• Not cleared by the liver (unlike insulin), providing more stable levels
• Longer half-life than insulin
• Not affected by exogenous insulin administration (no cross-reactivity in assays)
• More reliable in hemolyzed samples (insulin levels can be underestimated in hemolyzed blood, which is common during prolonged fasting tests) 3

Insulin: Less Reliable but Still Useful

Insulin measurement has limitations: 5

• Cleared by the liver, causing variable levels
• Some insulin assays have cross-reactivity with proinsulin (up to 40%), potentially overestimating true insulin
• Insulin-specific assays (without proinsulin cross-reactivity) may show insulin <6 µU/mL or even <3 µU/mL in some insulinoma patients, particularly those with small tumors 5
• Can be underestimated in hemolyzed samples 3

Proinsulin: The Most Specific Marker

Proinsulin >5 pmol/L during hypoglycemia (glucose <2.5 mmol/L) achieves 100% sensitivity and specificity for endogenous hyperinsulinism. 4 Proinsulin is particularly valuable because:

• It is the precursor molecule that is cleaved to produce insulin and C-peptide
• Elevated levels indicate active beta-cell secretion
• Less affected by assay variability than insulin
• May identify endogenous hyperinsulinism even at higher glucose levels (2.5-3.3 mmol/L) when proinsulin >22 pmol/L 4

Recommended Diagnostic Approach

The Endocrine Society recommends measuring all three markers simultaneously during documented hypoglycemia (glucose <55 mg/dL or 3.0 mmol/L): 1

1. Plasma glucose (confirm hypoglycemia)
2. Insulin
3. C-peptide
4. Proinsulin
5. β-hydroxybutyrate (should be ≤2.7 mmol/L if insulin-mediated)
6. Screen for oral hypoglycemic agents
7. Insulin antibodies
8. Glucagon stimulation test (glucose should rise ≥25 mg/dL if insulin-mediated)

If spontaneous hypoglycemia cannot be observed, perform a supervised 72-hour fast or mixed-meal test to recreate the conditions. 1

Critical Thresholds Summary

Parameter	Normal Response to Hypoglycemia	Endogenous Hyperinsulinism
Glucose	<55 mg/dL (3.0 mmol/L)	<55 mg/dL (3.0 mmol/L)
Insulin	<3 µU/mL (18 pmol/L)	≥3 µU/mL (18 pmol/L)
C-peptide	<0.6 ng/mL (0.2 nmol/L)	≥0.6 ng/mL (0.2 nmol/L)
Proinsulin	<5.0 pmol/L	≥5.0 pmol/L

1, 2

Important Caveats

Renal insufficiency invalidates standard thresholds because C-peptide is renally cleared; use β-hydroxybutyrate and glucagon stimulation instead. 2

Hepatic insufficiency and post-pancreatectomy patients have not had thresholds validated; interpret with caution. 2

Laboratories must validate cutoffs using their specific assay platforms, as inter-assay variability remains significant. 2

Small insulinomas may produce lower insulin and C-peptide levels than large tumors, but proinsulin remains elevated. 5